The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects

Infection. 2022 Apr;50(2):541-543. doi: 10.1007/s15010-021-01680-z. Epub 2021 Aug 3.

Authors

Affiliations

¹ Department of Medical Biotechnologies, University of Siena, Siena, Italy.
² Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35121, Padova, Italy.
³ Belluno Hospital, Belluno, Italy.
⁴ Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35121, Padova, Italy. saverio.parisi@unipd.it.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing
BNT162 Vaccine*
COVID-19* / prevention & control
Humans
SARS-CoV-2
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Neutralizing
Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine

Grants and funding